Publications by authors named "Meihe Wu"
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.
Nephrol Dial Transplant
October 2024
Article Synopsis
- Rituximab is effective for treating primary membranous nephropathy but has limited response rates; obinutuzumab, a stronger B-cell depleting antibody, may show better outcomes.
- A study at Huashan Hospital compared the effectiveness of obinutuzumab and rituximab in adult patients resistant to traditional treatments from 2015 to 2024, focusing on overall remission and safety.
- Results revealed a much higher response rate for obinutuzumab (90%) compared to rituximab (38.7%), along with better immunological remission rates, while both treatments had similar safety profiles.